

**Table 2. Overview of TEAEs and most common TEAEs (occurring in  $\geq 5\%$  of patients in any treatment arm) for patients with SGS in Studies 342 and 412 (Safety Analysis Set)<sup>a</sup>**

	<b>Study 342<sup>b</sup></b> <b>(n=52)</b>	<b>Study 412</b> <b>(n=16)</b>
<b>Any TEAEs, n (%)</b>	39 (75.0)	13 (81.3)
<b>Any treatment-related TEAE, n (%)</b>	28 (53.8)	9 (56.3)
<b>Any TEAE leading to treatment discontinuation, n (%)</b>	3 (5.8)	2 (12.5)
<b>Any serious TEAE, n (%)</b>	8 (15.4)	3 (18.8)
<b>TEAEs occurring in (<math>\geq 5\%</math> of participants in any treatment arm)</b>		
<b>Dizziness</b>	19 (36.5)	8 (50.0)
<b>Somnolence<sup>c</sup></b>	8 (15.4)	1 (6.3)
<b>Nasopharyngitis<sup>d</sup></b>	6 (11.5)	1 (6.3)
<b>Headache</b>	4 (7.7)	1 (6.3)
<b>Epilepsy</b>	4 (7.7)	0 (0.0)
<b>Stomatitis</b>	3 (5.8)	0 (0.0)
<b>Weight increased</b>	2 (3.8)	1 (6.3)
<b>Depression</b>	1 (1.9)	1 (6.3)
<b>Dysarthria</b>	1 (1.9)	1 (6.3)
<b>Paraesthesia</b>	1 (1.9)	1 (6.3)
<b>Seizure</b>	0 (0.0) <sup>e</sup>	1 (6.3)
<b>Anger</b>	0 (0.0)	1 (6.3)
<b>Clavicle fracture</b>	0 (0.0)	1 (6.3)
<b>Facial edema</b>	0 (0.0)	1 (6.3)
<b>Head trauma</b>	0 (0.0)	1 (6.3)
<b>Hypoaesthesia</b>	0 (0.0)	1 (6.3)
<b>Lethargy</b>	0 (0.0)	1 (6.3)
<b>Lip laceration</b>	0 (0.0)	1 (6.3)
<b>Memory impairment</b>	0 (0.0)	1 (6.3)
<b>Muscle cramp</b>	0 (0.0)	1 (6.3)
<b>Suicide attempt</b>	0 (0.0)	1 (6.3)

<sup>a</sup>Patients with  $\geq 2$  events occurring in a single category were counted only once; <sup>b</sup>MedDRA version 21.0; <sup>c</sup>Includes “drowsiness”; <sup>d</sup>Includes “common cold”; <sup>e</sup>“Seizure” Preferred Term not reported, however one patient reported POS with SGS

MedDRA, Medical Dictionary for Regulatory Activities; POS, partial-onset seizures; SGS, secondarily generalized seizures; TEAE, treatment-emergent adverse event